MET and glioblastoma: In glioblastoma, the overexpression of MET with predominant weak-to-moderate staining intensity was observed in 23% of unamplified glioblastomas, and only strong immunostaining was suggested to be appropriate for the assessment of MET amplification [37], which might also suggest other mechanisms of MET overexpression.